Morphocell Technologies Inc.

Morphocell Technologies Inc. , based in Canada, is a biotechnology firm dedicated to developing advanced tissue engineering solutions to combat liver diseases, particularly through their flagship product, ReLiver®. Founded in 2018 in Laval, Canada, Morphocell Technologies specializes in innovative approaches to tissue engineering for liver health. The company raised USD 10.

00 mn in Series A funding in December 2025, led by Investment Quebec with participation from CDP Venture Capital. Morphocell has successfully completed 2 deals to date. Morphocell Technologies specializes in advanced tissue engineering, focusing on innovative solutions for liver diseases. Their core product, ReLiver®, is designed to deliver effective treatments for severe liver conditions through engineered tissues that aim to replicate the functions of healthy liver cells.

The technology is intended for use in both adult and pediatric populations, addressing critical medical needs for patients suffering from liver dysfunction. The company actively collaborates with research institutions and other organizations, such as CQDM and the Stem Cell Network, to develop regenerative therapies for pediatric urea cycle disorders. Morphocell's products target markets primarily in North America and Europe, where they seek to provide groundbreaking therapeutic options to healthcare providers and specialists in hepatology. Morphocell Technologies has recently completed a USD 10.

00 mn Series A financing round, indicating strong investor interest and potential for revenue generation. The company’s revenue structure is grounded in business-to-business arrangements, primarily involving partnerships with healthcare institutions and pharmaceutical companies. Through these collaborations, Morphocell supplies its flagship product, ReLiver®, as part of clinical trials or therapeutic applications in hospital settings. Transactions may occur through direct partnerships or licensing agreements, enabling healthcare providers to integrate Morphocell's engineered tissues into their treatment protocols.

The company's revenue generation strategy is poised to evolve as clinical success and regulatory approvals progress, potentially leading to wider adoption of their innovative liver disease therapies. In December 2025, Morphocell Technologies will utilize the USD 10. 00 mn raised in Series A funding to advance its ReLiver program toward clinical proof-of-concept, expand manufacturing capacity, and establish a European subsidiary in Italy. The company plans to explore new markets in Europe, aiming to launch its products in additional regions by 2026, facilitating broader access to its innovative therapies for liver diseases.